U.S. market Closed. Opens in 4 hours 18 minutes

CDXC | ChromaDex Corporation Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 7.26 - 7.61
52 Week Range 1.3200 - 7.67
Beta 1.78
Implied Volatility 97.15%
IV Rank 6.28%
Day's Volume 570,827
Average Volume 1,102,829
Shares Outstanding 76,383,300
Market Cap 572,874,750
Sector Healthcare
Industry Biotechnology
IPO Date 2008-06-25
Valuation
Profitability
Growth
Health
P/E Ratio 375.00
Forward P/E Ratio N/A
EPS 0.02
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 106
Country USA
Website CDXC
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
CDXC's peers: IKNA, ENOB, ELYM, HCWB, XCUR, IPSC, KZR, MLYS, NKTX, NGM, AVTE, ADAG, ACRV, RZLT, ANTX, ANEB, JANX, CYT, MNOV
*Chart delayed
Analyzing fundamentals for CDXC we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is on medium level and Health is passable. For more detailed analysis please see CDXC Fundamentals page.

Watching at CDXC technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on CDXC Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙